HHS & Healthcare Contracts Intelligence — July 24, 2026

Leidos Biomedical Research Inc. won a $173.3 million cost-plus-fixed-fee delivery order from the NIH National Cancer Institute for next-generation vaccine clinical trials. The cost-plus structure minimizes profit volatility, and the six-year term (2023-2029) with $36.8 million already outlaid provides long-term revenue visibility of ~$28.9 million annually.

The $173.3 million delivery order is not fully funded; only $36.8 million has been obligated to date. Future funding depends on NIH budget appropriations and program prioritization, which could be affected by federal budget negotiations or Continuing Resolutions.

The contract involves Phase 1 and Phase 2 clinical trials for next-generation vaccines. Clinical trial outcomes are inherently uncertain; negative trial results could reduce follow-on funding or future contract opportunities for Leidos.

Leidos' win under full and open competition demonstrates competitive strength in NIH health R&D services. Successful vaccine trial outcomes could lead to expanded contracts, follow-on Phase 3 trials, or production-related awards from the NIH or other HHS agencies.

The NIH National Cancer Institute awarded a six-year, $173.3 million delivery order to Leidos, reflecting sustained federal investment in vaccine development and clinical research. The cost-plus-fixed-fee structure indicates predictable, low-risk revenue streams for contractors in this niche.

{"entity"=>"Leidos Holdings, Inc. (LDOS)", "reason"=>"Leidos holds a $173.3 million NIH vaccine contract with only $36.8 million currently funded. Future funding obligations and trial outcomes will determine the contract's full revenue contribution.", "trigger"=>"NIH budget announcements, future obligation notices under this delivery order, and clinical trial result disclosures"}

{"entity"=>"Health R&D Services Sector", "reason"=>"NIH's consistent funding for vaccine R&D signals stable demand for clinical trial services. Competitor wins or losses in similar NIH competitions will indicate competitive dynamics.", "trigger"=>"NIH National Cancer Institute contract awards to other vendors (e.g., IQVIA, PPD, Charles River Laboratories)"}